(Q39580496)

13 September 2017

title

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial (English)

1 reference

13 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

Andreas H Diacon

1

1 reference

13 September 2017

Rodney Dawson

2

1 reference

13 September 2017

Florian von Groote-Bidlingmaier

3

1 reference

13 September 2017

Gregory Symons

4

1 reference

13 September 2017

Amour Venter

5

1 reference

13 September 2017

Peter R Donald

6

1 reference

13 September 2017

Christo van Niekerk

7

1 reference

13 September 2017

Daniel Everitt

8

1 reference

13 September 2017

Helen Winter

9

1 reference

13 September 2017

Piet Becker

10

1 reference

13 September 2017

Carl M Mendel

11

1 reference

13 September 2017

Melvin K Spigelman

12

1 reference

13 September 2017

language of work or name

English

0 references

publication date

23 July 2012

1 reference

13 September 2017

1 reference

13 September 2017

volume

380

1 reference

13 September 2017

issue

9846

1 reference

13 September 2017

page(s)

986-993

1 reference

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Phase II dose-ranging trial of the early bactericidal activity of PA-824

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

The early bactericidal activity of anti-tuberculosis drugs: a literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

Early bactericidal activity of antituberculosis agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961080-0

7 January 2021

10.1016/S0140-6736(12)61080-0

Identifiers

DOI

1 reference

13 September 2017

1 reference